View Item 

Show simple item record

Becaplermin gel in the treatment of pressure ulcers: a phase II randomized, double-blind, placebo-controlled study

dc.contributor.authorRees, Riley S.en_US
dc.contributor.authorRobson, Martin C.en_US
dc.contributor.authorSmiell, Janice M.en_US
dc.contributor.authorPerry, Barbara H.en_US
dc.date.accessioned2010-06-01T18:58:54Z
dc.date.available2010-06-01T18:58:54Z
dc.date.issued1999-05en_US
dc.identifier.citationRees, Riley S; Robson, Martin C; Smiell, Janice M; Perry, Barbara H (1999). "Becaplermin gel in the treatment of pressure ulcers: a phase II randomized, double-blind, placebo-controlled study." Wound Repair and Regeneration 7(3): 141-147. <http://hdl.handle.net/2027.42/72172>en_US
dc.identifier.issn1067-1927en_US
dc.identifier.issn1524-475Xen_US
dc.identifier.urihttps://hdl.handle.net/2027.42/72172
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=10417749&dopt=citationen_US
dc.format.extent378308 bytes
dc.format.extent3109 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherBlackwell Science Incen_US
dc.rightsCopyright © 1999 by The Wound Healing Society.en_US
dc.titleBecaplermin gel in the treatment of pressure ulcers: a phase II randomized, double-blind, placebo-controlled studyen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelMedicine (General)en_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationother  Ann Arbor, MI; Institute for Tissue Regeneration, Repair, and Rehabilitation,en_US
dc.contributor.affiliationother  Bay Pines, FL; and the R.W. Johnson Pharmaceutical Research Institute,en_US
dc.contributor.affiliationother  Raritan, NJ.en_US
dc.identifier.pmid10417749en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/72172/1/j.1524-475X.1999.00141.x.pdf
dc.identifier.doi10.1046/j.1524-475X.1999.00141.xen_US
dc.identifier.sourceWound Repair and Regenerationen_US
dc.identifier.citedreference1  The National Pressure Ulcer Advisory Panel. Pressure ulcer prevalence, cost and risk assessment. Consensus development conference statement. Decubitus 1989; 2: 24 8.en_US
dc.identifier.citedreferenceSmith DM. Pressure ulcers in the nursing home. Ann Intern Med 1995; 123: 433 42.en_US
dc.identifier.citedreferenceAllman RM. Pressure ulcers among the elderly. N Engl J Med 1989; 320: 850 3.en_US
dc.identifier.citedreferenceAllman RM. Pressure ulcer prevalence, incidence, risk factors, and impact. Clin Geriatr Med 1997; 13: 421 36.en_US
dc.identifier.citedreferenceJavitz HS, Ward MM, Martens L. Major costs associated with pressure sores. J Wound Care 1998; 7: 286 90.en_US
dc.identifier.citedreferenceAllman RM, Laprade CA, Noe LB, Walker JM, Moorer CA, Dear MR, Smith CR. Pressure sores among hospitalized patients. Ann Intern Med 1986; 105: 337 42.en_US
dc.identifier.citedreferenceBergstrom N, Allman RM, Alvarez OM, Bennett MA, Carlson CE, Frantz RA, Garber SL, Jackson BS, Kaminski Mv Jr, Kemp MG, Krouskop TA, Lewis Vl Jr, Maklebust J, Margolis DJ, Marvel EM, Reger SI, Rodeheaver GT, Salcido R, Xakellis GC, Yarkony GM. Treatment of pressure ulcers. Clinical Practice Guideline, no. 15. AHCPR Publication no. 95–0652, 1–154. Rockville, MD: U.S. Department of Health and Human Services. Public Health Service, Agency for Health Care Policy and Research, 1994.en_US
dc.identifier.citedreferenceRoss R. Platelet-derived growth factor. Lancet 1989; 1: 1179 989.en_US
dc.identifier.citedreferenceGrotendorst GR, Martin GR, Pencev D, Sodek J, Harvey AK. Stimulation of granulation tissue formation by platelet-derived growth factor in normal and diabetic rats. J Clin Invest 1985; 76: 2323 9.en_US
dc.identifier.citedreferenceSteed DL & the Diabetic Ulcer Study Group. Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity diabetic ulcers. J Vasc Surg 1995; 21: 71 81.en_US
dc.identifier.citedreferenceWieman TJ, Smiell JM, Su Y. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers: a phase III, randomized, placebo-controlled, double-blind study. Diabetes Care 1998; 21: 822 7.en_US
dc.identifier.citedreferenced'hemecourt PA, Smiell JM, Karim MR. Sodium carboxymethylcellulose aqueous-based gel vs. becaplermin gel in patients with nonhealing lower extremity diabetic ulcers. Wounds 1998; 10: 69 75.en_US
dc.identifier.citedreferenceRovee DT, Kurowsky CA, Labun J. Local wound environment and epidermal healing. Arch Dermatol 1972; 106: 330 4.en_US
dc.identifier.citedreferenceRobson MC, Thomason A, Pierce GF, Robson LE. Platelet-derived growth factor BB for the treatment of chronic pressure ulcers. Lancet 1992; 339: 23 5.en_US
dc.identifier.citedreference15  Data on file. The R. W. Johnson Pharmaceutical Research Institute.en_US
dc.identifier.citedreferenceMustoe TA, Cutler NR, Allman RM, Goode PS, Deuel TF, Prause JA, Bear M, Serdar CM, Pierce GF. A phase II study to evaluate recombinant platelet-derived growth factor-BB in the treatment of stage 3 and 4 pressure ulcers. Arch Surg 1994; 129: 213 9.en_US
dc.identifier.citedreferenceResch CS, Kerner E, Robson MC, Heggers JP, Scherer M, Boertman JA, Schileru R. Pressure sore volume measurement. A technique to document and record wound healing. J Am Geriatr Soc 1988; 36: 444 6.en_US
dc.identifier.citedreferencePecoraro RE, Ahroni JH, Boyko EJ, Stensel VL. Chronology and determinants of tissue repair in diabetic lower-extremity ulcers. Diabetes 1991; 40: 1305 13.en_US
dc.identifier.citedreferenceAllman RM & Fowler E. Expected outcomes for the treatment of pressure ulcers. Adv Wound Care 1995; 8 ( 4 Suppl. ): 59 60.en_US
dc.identifier.citedreferencePerdup A. The healing rate of leg ulcers. A clinical and statistical study of 233 patients hospitalized with leg ulcers. Acta Derm Venereol 1972; 52: 136 40.en_US
dc.identifier.citedreferenceRobson MC, Maggi SP, Smith PD, Wassermann RJ, Mosiello GC, Hill DP, Cooper DM. Ease of wound closure as an endpoint of treatment efficacy. Wound Rep Reg 1999; 7: 20 6.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1524-475X.1999.00141.x.pdf
Size:
369.4KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.